NCT06118931

Brief Summary

This study will evaluate the effectiveness of time-restricted eating (TRE), which is a form of intermittent fasting. When performing TRE, individuals consume all of their calories within a specific time window and then only consume water or other no calorie drinks the rest of the day. TRE is performed each day. There is no restriction on the quality or amount of food that people can consume during their eating window (ad libitum eating) with TRE, which can last anywhere from 4 to 12 hours. We are comparing three different 9-hour eating windows to determine whether the start and stop time of the eating window impact blood sugar control in individuals with obesity who also have or are at risk for type 2 diabetes. We also aim to determine if there are differences in the effects of the timing of eating window between males and females.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable diabetes-mellitus-type-2

Timeline
14mo left

Started Jun 2025

Typical duration for not_applicable diabetes-mellitus-type-2

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress43%
Jun 2025Jun 2027

First Submitted

Initial submission to the registry

October 31, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 7, 2023

Completed
1.6 years until next milestone

Study Start

First participant enrolled

June 28, 2025

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 28, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 28, 2027

Last Updated

October 2, 2025

Status Verified

September 1, 2025

Enrollment Period

2 years

First QC Date

October 31, 2023

Last Update Submit

September 26, 2025

Conditions

Keywords

Time-restricted eatingType 2 DiabetesObesityGlycemic Control

Outcome Measures

Primary Outcomes (1)

  • Average 24-hour glucose total area under the curve (AUC) over 7 days

    Assessed for 7 continuous days using a continuous glucose monitor.

    7 days

Secondary Outcomes (8)

  • Average 24-hour glucose over 7 days

    7 days

  • Average daily nocturnal glucose over 7 evenings

    7 days

  • Average daily time spent in hyperglycemia over 7 days

    7 days

  • Postprandial glucose

    2 hours

  • Glycemic viability

    7 days

  • +3 more secondary outcomes

Other Outcomes (6)

  • Dietary intake

    7 days

  • Weight change

    7 days

  • Blood pressure change

    7 days

  • +3 more other outcomes

Study Arms (4)

Early (7:00-16:00h) TRE

EXPERIMENTAL

Participants will be asked to eat ad libitum between the hours of 7:00 - 16:00 each day for seven days, and then only drink water or other no calorie beverages for the rest of the day. On the 8th day, they will consume one meal replacement beverage at 7:00 and be instructed to not consume anything else for two hours. After the two hours they will be instructed to return to their normal baseline eating habits.

Behavioral: Early (7:00 - 16:00) TRE

Mid (9:30-18:30h) TRE

EXPERIMENTAL

Participants will be asked to eat ad libitum between the hours of 9:30 - 18:30 each day for seven days, and then only drink water or other no calorie beverages for the rest of the day. On the 8th day, they will consume one meal replacement beverage at 9:30 and be instructed to not consume anything else for two hours. After the two hours they will be instructed to return to their normal baseline eating habits.

Behavioral: Mid (9:30 - 18:30) TRE

Late (12:00-21:00h) TRE

EXPERIMENTAL

Participants will be asked to eat ad libitum between the hours of 12:00 - 21:00 each day for seven days, and then only drink water or other no calorie beverages for the rest of the day. On the 8th day, they will consume one meal replacement beverage at 12:00 and be instructed to not consume anything else for two hours. After the two hours they will be instructed to return to their normal baseline eating habits.

Behavioral: Late (12:00 - 21:00) TRE

Control

NO INTERVENTION

During the first week of the study, participants will be asked to eat as they normally do, and to not make any changes regarding when they are stopping or starting eating.

Interventions

A standardized TRE Protocol where participants eat ad libitum between the hours of 7:00 to 16:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 7:00, and not consume anything else for two hours.

Early (7:00-16:00h) TRE

A standardized TRE Protocol where participants eat ad libitum between the hours of 9:30 to 18:30 for 7 days. On the 8th day, they will consume a meal replacement beverage at 9:30, and not consume anything else for two hours.

Mid (9:30-18:30h) TRE

A standardized TRE Protocol where participants eat ad libitum between the hours of 12:00 to 21:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 12:00, and not consume anything else for two hours.

Late (12:00-21:00h) TRE

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged \>18 years
  • Body mass index \>30 kg/m2 and \<50 kg/m2
  • Have access to an Apple or Android cellphone with Bluetooth.
  • Have type 2 diabetes or be at risk for type 2 diabetes (defined as high (33+) Canadian Diabetes Risk Score)

You may not qualify if:

  • Individuals with type 2 diabetes will be excluded if: (1) currently on \>3 monotherapies for diabetes, (2) have had diabetes therapy dosage changes \<3 months, (3) self-reported hemoglobin A1c \>9.0%, (4) taking exogenous insulin, or (5) taking sulfonylureas
  • History of or referral for bariatric surgery
  • Weight loss \>5% in the last 3 months
  • Taking antiobesity (weight loss) medications
  • Body weight \>340lbs
  • Diagnosed cognitive disorder that precludes them from giving consent
  • Inability or unwillingness to change their eating window to follow those prescribed in the study
  • Currently eating during \<12 hour period on 5 or more days/week
  • Physician-diagnosed eating disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Remote Ontario-wide

Toronto, Ontario, Canada

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus, Type 2ObesityPrediabetic StateHyperglycemiaIntermittent Fasting

Interventions

Trehalase

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsFastingFeeding BehaviorBehavior

Intervention Hierarchy (Ancestors)

DisaccharidasesGlycoside HydrolasesHydrolasesEnzymesEnzymes and Coenzymes

Study Officials

  • Amy A. Kirkham, PhD

    University of Toronto

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Amy A Kirkham, PhD

CONTACT

Rebecca AG Christensen, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 31, 2023

First Posted

November 7, 2023

Study Start

June 28, 2025

Primary Completion (Estimated)

June 28, 2027

Study Completion (Estimated)

June 28, 2027

Last Updated

October 2, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations